BiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by began coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

BiondVax Pharmaceuticals Price Performance

Shares of BVXV opened at $1.81 on Friday. BiondVax Pharmaceuticals has a 1 year low of $1.70 and a 1 year high of $13.90. The company has a debt-to-equity ratio of 5.92, a current ratio of 4.28 and a quick ratio of 6.15. The company has a market capitalization of $3.38 million, a price-to-earnings ratio of -0.51 and a beta of 2.47. The business has a 50-day moving average of $1.98 and a 200-day moving average of $4.00.

BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) last issued its quarterly earnings data on Monday, April 17th. The company reported ($0.30) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On BiondVax Pharmaceuticals

An institutional investor recently raised its position in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. boosted its holdings in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXVGet Rating) by 226.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 163,423 shares of the company’s stock after purchasing an additional 113,418 shares during the quarter. Envestnet Asset Management Inc. owned about 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent quarter.

BiondVax Pharmaceuticals Company Profile

(Get Rating)

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza.

Featured Stories

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with's FREE daily email newsletter.